Author(s): Edwards JD; Li Z; McFarlane P; Rabi DM; Gilbert J; Bajaj HS; MacIntosh BJ; Bittman J; Feldman RD; Dresser G; Terenzi K; Swartz R; Gabor J; Pearson GJ; Selby P; Wharton S; Warburton DER; Pakhalé S; Styra R; Baker B; Tu K; Hawkins M; Stone ...

Background: Although brain and heart conditions share overlapping risk factors and commonly co-occur, current cardiac and neurologic clinical guidelines are typically produced within specialty silos. The objective of this guideline from a Canadian Cardiovascular Harmonized National Guideline Ende ...

Article GUID: 41912243

Author(s): Smith EE; Phillips NA; Feldman HH; Borrie M; Ganesh A; Henri-Bhargava A; Desmarais P; Frank A; Badhwar A; Barlow L; Bartha R; Best S; Bethell J; Bhangu J; Black SE; Bocti C; Bronskill SE; Burhan AM; Calon F; Camicioli R; Campbell B; Coll ...

Lecanemab and donanemab are monoclonal antibody therapies that remove amyloid-beta from the brain. They are the first therapies that alter a fundamental mechanism, amyloid-beta deposition, in Alzheimer disease (AD). To inform Canadian decisions on approval and use of these drugs, the Canadian Con ...

Article GUID: 39893139